ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1040

Combined High-Resolution Single Photon Emission Computed Tomography and Magnetic Resonance Imaging for Therapy Monitoring in Rheumatoid Arthritis

Philipp Sewerin1, Christian Buchbender2, Katalin Mattes-György3, Falk Miese2, Hans-Jörg Wittsack2, Christof Specker4, Gerald Antoch2, Matthias Schneider5, Axel Scherer2 and Ben Ostendorf1, 1Endocrinology, Diabetology and Rheumatology, Heinrich-Heine-University, Düsseldorf, Germany, 2Diagnostic and Interventional Radiology, Heinrich-Heine-University, Düsseldorf, Germany, 3Nuclear Medicine, Heinrich-Heine-University, Düsseldorf, Germany, 4Department of rheumatology and clinical immunology, Hospital Essen Sued, Essem, Germany, 5Endocrinology, Diabetology and Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: joint destruction, Magnetic resonance imaging (MRI), positron emission tomography (PET) and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Imaging of Rheumatic Diseases: Magnetic Resonance Imaging, Computed Tomography and X-ray

Session Type: Abstract Submissions (ACR)

Background/Purpose:

To evaluate whether combined multi-pinhole single photon emission computed tomography (MPH-SPECT) with technetium-99m-labelled disphosphonates (Tc99m-DPD) and magnetic resonance imaging (MRI) detect changes in inflammation in early rheumatoid arthritis (ERA) patients under methotrexat (MTX) therapy and to investigate the relation between Tc99m-DPD uptake and the development of erosion.

Methods:

MPH-SPECT and MRI of metacarpophalangeal joints (MCP) have been prospectively performed in 10 consecutive ERA patients (8 female, 2 male; 49 ± 13 years [mean ± SD]), range: 24 – 68) prior to and 6 months after initiation of MTX. The Tc99m-DPD uptake was measured using a region of analysis. The course of synovitis, bone marrow edema (BME) and erosions were scored according to the Rheumatoid Arthritis MRI Score (RAMRIS) criteria.

Results:

The frequency of increased Tc99m-DPD uptake, synovitis and BME decreased under MTX therapy; but the number of bone erosions increased. Joints with progressive and newly developed erosions on follow-up had a higher baseline Tc99m-DPD uptake (2.64 ±1.23 vs. 1.43 ±0.91) (p< 0.001). Joints with persistent synovitis did not show higher Tc99m-DPD uptake values (1.56 ±1.27 vs. 1.47 ± 0.75) (p= 0.74). There was no correlation between persistence of synovitis and the development of erosions (Fc= 0.3, p= 0.12).

Conclusion:

Persistence of synovitis seems to be independent from Tc99m-DPD uptake and the development of erosions, while early increased bone metabolism is found in MCP joints which show erosive progression under MTX therapy. Hybrid MPH-SPECT and MRI might thus provide valuable additional information for individual risk-stratified therapeutic decisions.


Disclosure:

P. Sewerin,
None;

C. Buchbender,
None;

K. Mattes-György,
None;

F. Miese,
None;

H. J. Wittsack,
None;

C. Specker,
None;

G. Antoch,
None;

M. Schneider,
None;

A. Scherer,
None;

B. Ostendorf,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/combined-high-resolution-single-photon-emission-computed-tomography-and-magnetic-resonance-imaging-for-therapy-monitoring-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology